European CHMP recommends approval of tafasitamab (Minjuvi) for treatment of relapsed or refractory diffuse large B‑cell lymphoma (DLBCL)

Tafasitamab is a monoclonal antibody that targets the CD19 antigen expressed on the surface of pre-B and mature B lymphocytes and is intended for the treatment of adults with relapsed or refractory disease ineligible for autologous stem cell transplant.

European Medicines Agency